The Patent Finder

Iterative Therapeutics, Inc.

Also on record
Records under this name other than patents Iterative Therapeutics, Inc. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned.

Showing 1 to 5 of 5 · Back to Iterative Therapeutics, Inc.

PatentTitleStatus Expires Confidence
US 7,511,121Polymeric immunoglobulin fusion proteins that target low-affinity Fcγreceptors
Term ended
Term ended Nov 29, 2022 · From the USPTO record
Term endedTerm ended Nov 29, 2022From the USPTO record
US 7,897,729Polymeric immunoglobulin fusion proteins that target low affinity FcγReceptors
Term ended
Ended no later than Mar 11, 2022 · From the USPTO record
Term endedEnded no later than Mar 11, 2022From the USPTO record
US 8,163,289Methods and Compositions Involving Polymeric Immunoglobulin Fusion Proteins
Term ended
Term ended Mar 11, 2022 · Medium confidence
Term endedTerm ended Mar 11, 2022Medium confidence
US 8,986,698Method of using fusion proteins
Term ended
Term ended Mar 11, 2022 · From the USPTO record
Term endedTerm ended Mar 11, 2022From the USPTO record
US 9,127,063Nucleic acids related to fusion proteins
Term ended
Term ended Mar 11, 2022 · From the USPTO record
Term endedTerm ended Mar 11, 2022From the USPTO record
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 17, 2026 · includes USPTO assignment data published Nov 16, 2026, status data published Nov 17, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited